How would you treat metastatic NSCLC in a non-smoker with bone biopsy showing adenocarcinoma of lung origin but inadequate tissue for mutational panel or PD-L1?
Lung primary is inaccessible for biopsy and metastatic sites are only 2 small bone lesions. In a non-smoker, a driver mutation is suspected but would you forego that forgo and consider chemotherapy +/- immunotherapy?
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Wexner Medical Center at The Ohio State University
Answered on
Molecular studies and PDL1 have become standard for patients with advanced/metastatic lung adenocarcinoma. We feel particularly strongly about doing this (molecular studies) in the never smoker, however all adenocarcinomas (and selected squamous cancers) should have this done. Cytology specimens (du...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Siri Onclogy and hematology Infusion Service
Answered on
However, unfortunately, the only FDA approved plasma test is the Roche test for EGFR mutations. This has a reasonable sensitivity for EGFR mutations by about 85% in patients who were untreated but were able to have the tissue biopsy. In a patient with insufficient tissue, the yield may be lower, giv...
Join for free or sign in to see the full answer